Professional paper

What is New in the Most Recent Guidelines for the Management of Dyslipidemias of the European Society of Cardiology and the European Atherosclerosis Society?

Boško Skorić ; University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia

Abstract

The most recent Guidelines for the management of dyslipidemias of the European Society of Cardiology and the European Atherosclerosis Society arrived after two major studies that demonstrated the efficiency of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), as well as the key fact that every additional reduction of LDL cholesterol reduces increased cardiovascular risk, i.e. that there is no lower limit of target blood concentration of LDL cholesterol. The latter was reflected in the recommendation of significantly lower target values of LDL cholesterol, especially for people with high and very high cardiovascular risk, resulting in the recognition of the need to combine statins with other hypolipemic agents, primarily ezetimibe followed by PCSK9i. Omega-3 fatty acids are recommended for the treatment of high-risk patients with hypertriglyceridemia despite statin treatment. Some modifications were made to cardiovascular risk categories, primarily for patients with diabetes mellitus and familial hypercholesterolemia, and more importance has been assigned to determining apolipoprotein B and lipoprotein(a) for more precise assessment of cardiovascular risk. We are now tasked with investing significant efforts into implementing these recommendations in our daily clinical practice in order to further reduce the population burden of cardiovascular diseases.

Keywords

dyslipidemias; guidelines; management; cardiovascular risk

Hrčak ID:

250415

URI

https://hrcak.srce.hr/250415

Publication date:

18.1.2021.

Article data in other languages: croatian

Visits: 7.607 *